The use of antihyperglycemic therapy in the management of type 2 diabetes should be individualized on the basis of effectiveness and tolerability.
Selecting the starting dose of Poze G should be based on the patient’s current regimen of pioglitazone and/or sulfonylurea. It is recommended that a single dose of Poze G be administered once daily with the first main mea.
Starting dose for patients currently on glimepiride monotherapy
Based on the usual starting dose of pioglitazone (15 mg or 30 mg daily), Poze G may be initiated at 30 mg/2 mg or 30 mg/4 mg tablet strengths once daily, and adjusted after assessing adequacy of therapeutic response.
Starting dose for patients currently on pioglitazone monotherapy
Based on the usual starting doses of glimepiride (1 mg or 2 mg once daily), and pioglitazone 15 mg or 30 mg, Poze G may be initiated at 30 mg/2 mg once daily, and adjusted after assessing adequacy of therapeutic response.
Starting dose for patients switching from combination therapy of pioglitazone plus glimepiride as separate tablets
Poze G may be initiated with 30 mg/2 mg or 30 mg/4 mg tablet strengths based on the dose of pioglitazone and glimepiride already being taken. Patients who are not controlled with 15 mg of pioglitazone in combination with glimepiride should be carefully monitored when switched to Poze G.
Maximum Recommended Dose
Poze G tablets are available as a 30 mg pioglitazone plus 2 mg glimepiride or a 30 mg pioglitazone plus 4 mg glimepiride formulation for oral administration. The maximum recommended daily dose for pioglitazone is 45 mg and the maximum recommended daily dose for glimepiride is 8 mg. Poze G should therefore not be given more than once daily at any of the tablet strengths.